X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat (FT-4202), is aligned with Novo Nordisk’s strategy to complement and accelerate its scientific presence and pipeline in haemoglobinopathies.
Lead Product(s): Etavopivat
Therapeutic Area: Genetic Disease Product Name: FT-4202
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million
Deal Type: Acquisition October 14, 2022
Details:
Under the terms of the agreement, Rigel Pharmaceuticals will develop, manufacture and commercialize FT-2102 (olutasidenib), an oral, small molecule inhibitor of mIDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia and other malignancies.
Lead Product(s): Olutasidenib,Cytarabine
Therapeutic Area: Oncology Product Name: FT-2102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rigel Pharmaceuticals
Deal Size: $235.0 million Upfront Cash: $2.0 million
Deal Type: Licensing Agreement August 02, 2022
Details:
FT-4202 (etavopivat) is designed to activate PKR and thereby modulate RBC metabolism by impacting two critical pathways in RBCs, will investigate whether decreasing 2,3-DPG may help oxygen bind to hemoglobin and thereby increase ATP and impact RBC function.
Lead Product(s): Etavopivat
Therapeutic Area: Genetic Disease Product Name: FT-4202
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation. In preclinical studies, FT-7501 demonstrated activity in both prostate cancer models that were sensitive.
Lead Product(s): FT-7051
Therapeutic Area: Oncology Product Name: FT-7051
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
FT-2102 (Olutasidenib) in combination with Vidaza (Azacitidine) is found to be well-tolerated and, yielded durable complete remission in the first Phase 2 combination trial in patients with the mIDH1 form of acute myeloid leukemia.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: FT-2102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Details:
Etavopivat, the company's investigational oral, once-daily, selective pyruvate kinase-R activator, significantly improved anemia and red blood cell health with a favorable tolerability and safety profile in patients with SCD.
Lead Product(s): Etavopivat
Therapeutic Area: Genetic Disease Product Name: FT-4202
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2021
Details:
FT-7051 is designed to attach to the CBP/p300 bromodomain potently and selectively, which then blocks androgen binding and reduces AR activation.
Lead Product(s): FT-7051
Therapeutic Area: Oncology Product Name: FT-7051
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
E-poster presentation includes initial data from the open-label extension cohort showing etavopivat improved and sustained hematologic and hemolytic parameters for patients living with sickle cell disease receiving 400 mg etavopivat once-daily for at least 2 to 12 weeks.
Lead Product(s): Etavopivat
Therapeutic Area: Genetic Disease Product Name: FT-4202
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
The Phase 1/2 study is a multicenter, open-label, multi-cohort evaluation of the safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of olutasidenib for patients with AML or myelodysplastic syndrome (MDS) with an IDH1 mutation.
Lead Product(s): Olutasidenib
Therapeutic Area: Oncology Product Name: FT-2102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
Doubling the dose of FT-4202 to 600 mg daily for 14 days compared to the previous 300 mg cohort was well-tolerated with no dose-limiting toxicities or treatment-related adverse events observed.
Lead Product(s): Etavopivat
Therapeutic Area: Genetic Disease Product Name: FT-4202
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
